To evaluate the efficacy and safety of subcutaneous and intravenous abatacept.

To evaluate the efficacy and safety of subcutaneous and intravenous abatacept. - Subcutaneous and abatacept versus intravenous abatacept.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013440

Enrollment

Registered

2014-03-18

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

SC abatacept IV abatacept Extension of SC abatacept

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who met the ACR 1987 revised criteria for the classification of RA. 2. Patients diagnosed as moderate disease activity (2.3<DAS28-CRP<4.1). 3. Anti-cyclic citrullinated peptide antibody >100 U/mL or rheumatoid factor >60 IU/mL.

Exclusion criteria

Exclusion criteria: Patients were excluded if they were previously treated with biological DMARDs.

Design outcomes

Primary

Measure	Time frame
The rate of patients completed 36 weeks with SC abatacept 2 weeks dose intervals.	—

Countries

Japan

Contacts

Public ContactShuzo Yoshida

Osaka Medical College Department of Internal Medicine (I)

in1307@poh.osaka-med.ac.jp+81-72-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026